Share on

MEA Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 5078
Pages: 145
Formats: report pdf report excel report power bi report ppt

MEA Gastroparesis Drugs Market Size (2024 to 2029)

The size of the Middle East and Africa Gastroparesis Drugs market was around USD 452.53 million in 2024. It is expected to grow at a CAGR of 3.8% to reach USD 549.29 million by 2029. It captures 8% of the global market.

Gastroparesis is a medical disorder in which the natural, spontaneous movement of the stomach muscles is restricted. Gastroparesis is becoming more common, as this is a type of gastroparesis with no known cause and symptoms of vomiting, nausea, and upper abdomen pain. Dietary adjustments, antiemetic medication, prokinetics medication, and symptoms modulators can all help with these symptoms.

An increase in the incidence rate of diabetes in the population, an increase in the number of surgical procedures, and an increase in the senior population are major factors promoting the growth of the gastroparesis drugs market in MEA. In addition, ongoing gastroparesis treatments, increase in the frequency of contractions and thus enhancing gastrointestinal motility, prokinetics medications are further estimated to contribute to the growth of the gastroparesis drugs market in the MEA region. Furthermore, according to the Centers for Disease Control and Prevention, approximately 44 million people in the United States had prediabetes in 2019, resulting in a significant prevalence of gastroparesis and influencing the regional market for gastroparesis treatment.

In addition, the rising frequency of diabetic mellitus in the Middle East and Africa is another key factor boosting the market growth. Diabetes is a common cause of gastroparesis, moving the gastroparesis medicine market ahead.

It creates blood sugar and nutrition problems, impairs proper digestion, and causes vomiting. Reglan, erythromycin, antiemetics, and a range of other medications and treatments are used to treat gastroparesis, which stimulates demand for specific therapies and the entire market to some extent. However, gastroparesis drug adverse effects, a lengthy regulatory process for therapeutic approval, and difficulty diagnosing gastroparesis could stall the market. Moreover, over the forecast period, the diabetic gastroparesis treatment market is anticipated to be restrained by a lack of scientific evidence on the improvement offered by prescription pharmaceuticals and the termination of clinical trials.

This research report on the Middle East and Africa gastroparesis drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, MEA is poised for robust growth in the forecast period due to increased investments by major companies in the market. In addition, a surge in demand for user-friendly pharmaceutical development, growing healthcare infrastructure, and creative marketing initiatives by top vendors in developing countries such as the UAE and Germany are expected to present profitable market expansion opportunities throughout the projection period.

KEY MARKET PLAYERS:

Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma is a few of the key players in the MEA gastroparesis drugs market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample